The spectrum of viruses inhibited by a genetically engineered consensus int
erferon (IFN) YM643 (interferon alfacon-1) was evaluated using a cytopathic
effect inhibition assay or plaque inhibition assay for five DNA viruses an
d 12 RNA viruses. This activity was compared to that of natural IFN-alpha d
erived from Namalwa lymphoblastoid cell line [IFN-alpha (Namalwa)]. The vir
uses inhibited by both IFNs were herpesvirus types 1 and 2, human cytomegal
ovirus, varicella-zoster virus, vesicular stomatitis virus, yellow fever vi
rus, bovine viral diarrhoea virus, Semliki Forest virus, western equine enc
ephalitis virus, encephalomyocarditis virus, rhinovirus type A, respiratory
syncytial virus, Newcastle disease virus and influenza virus type A (H1N1)
. Neither IFN inhibited coxsackie virus B1. reovirus type 3 or vaccinia vir
us in the experimental conditions used. The specific activity of YM643 in h
uman cells generally ranged from 3.6x10(7) to 2.1x10(9) IU/mg, which was gr
eater than that of IFN-alpha (Namalwa), which ranged from 3.1x10(6) to 4.6x
10(8) IU/mg against all sensitive viruses, except human cytomegalovirus and
rhinovirus type 1A, which displayed approximately equal sensitivity to bot
h IFNs. Significantly, the potency of YM643 against bovine viral diarrhoea
virus and yellow fever virus, which were selected to serve as surrogates of
hepatitis C virus, equalled or exceeded that of IFN-alpha (Namalwa). These
results suggest that the genetically engineered YM643 is more potent than
natural IFN-alpha.